New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection

Author(s): Ying Wang, Pui Man Hoi, Judy Yuet-Wa Chan, Simon M.-Y. Lee

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 14 , Issue 9 , 2014

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Indirubin is an active ingredient mainly used to treat leukemia in China and is reported to be a leading inhibitor of cyclindependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) by competing with ATP binding sites. New findings have indicated that its comprehensive structure may contribute to its polypharmacological activities particularly in cancer and neurodegenerative disease therapy, as both of these diseases are usually accompanied by a common molecular link related to abnormal phosphorylation of CDKs and GSK-3. In the elderly, cancer and neurodegenerative disease are tightly associated common diseases and sometimes unavoidably coexist. In this review, the underlying mechanisms of the dual actions of indirubin and its structurally-related compounds in cancer and neurodegenerative disease therapy are presented.

Keywords: cancer, CDKs, dual function, GSK-3, indirubin, neurodegeneration.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 09 October, 2014
Page: [1213 - 1219]
Pages: 7
DOI: 10.2174/1871520614666140825112924
Price: $65

Article Metrics

PDF: 43